EUCTR2018-000112-21-DE进行中（未招募）1 期
Prospective Window of opportunity trial 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer
Ruprecht-Karls-Universität Heidelberg, Medizinische Fakultät, vertreten durch das Universitätsklinikum Heidelberg0 个研究点目标入组 100 人开始时间: 2018年6月22日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Ability of subject to understand character and individual consequences of clinical trial
- •postmenopausal women, postmenopausal status is defined either by:
- •Prior bilateral oophorectomy
- •amenorrhea for 12 or more months
- •ER+, breast cancer, first diagnosed
- •breast cancers with a tumor size >/= cT1c.
- •Not legally incapacitated
- •Written informed consent (must be available before enrolment in the trial)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •prior breast cancer specific therapy
- •inflammatory cancers
- •Any medical condition (e.g. substance abuse) that may, in the clinical judgement of the investigator, independently influence the subject’s outcome during this study
- •Participation in other clinical trials or observation period of competing trials, respectively
- •missing written informed consent
- •missing understanding of German language
- •Previously included in this trial (no patient may be included more than once)
- •Current infection of any kind
- •Inflammation including autoimmune disease and active allergy
- •Breast feeding
研究者
相似试验
进行中（未招募）
1 期
A RANDOMISED, OPEN-LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEXAROTENE (TARGRETIN) CAPSULES COMBINED WITH PUVA, COMPARED TO PUVA TREATMENT ALONE IN PATIENTS WITH MYCOSIS FUNGOIDES.CUTANEOUS T CELL LYMPHOMA.EUCTR2004-003701-24-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER
已完成
不适用
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL OF WEEKLY PACLITAXEL PLUS AMG 386 OR PLACEBO IN WOMEN WITH RECURRENT PARTIALLY PLATINUM SENSITIVE OR RESISTANT EPITHELIAL OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCERS-C55 Malignant neoplasm of uterus, part unspecified-C56 Malignant neoplasm of ovaryMalignant neoplasm of uterus, part unspecifiedMalignant neoplasm of ovaryC55C56PER-116-10AMGEN INC.,6
进行中（未招募）
不适用
RANDOMIZED PHASE III TRIAL OF PREOPERATIVE VERSUS POSTOPERATIVE CHEMOTHERAPY WITH CISPLATIN AND GEMCITABINE IN STAGE IB-IIIA NON-SMALL CELL LUNG CANCER NSCLC - POP 01eoadjuvant treatmento for early stage non small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10061873Term: Non-small cell lung cancerEUCTR2006-002708-33-ITISTITUTI FISIOTERAPICI OSPITALIERI
招募中
1 期
PREOPERATIVE WINDOW OF OPPORTUNITY STUDY WITH GIREDESTRANT (GDC-9545) OR TAMOXIFEN IN PREMENOPAUSAL WOMEN WITH ER[+]/HER2[-] & KI67=10% EARLY BREAST CANCERCTIS2023-503565-36-00Medica Scientia Innovation Research S.L.92
进行中（未招募）
1 期
Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged =9 to <15 YearsDengue feverMedDRA version: 20.1Level: LLTClassification code 10012312Term: Dengue fever virus infectionSystem Organ Class: 100000004862EUCTR2022-003339-24-Outside-EU/EEATakeda Vaccines, Inc.